The goal of this case-control study is to evaluate the possible applicability of CXCL10, CXCL9, CCL20, and homocysteine as biomarkers of disease activity in vitiligo patients and to compare the levels of these markers with those in healthy controls.
The diagnosis and prognosis assessment in patients with vitiligo are essentially clinical. There are still no validated and established serological markers to objectively assist in defining disease activity. Objective: To evaluate the potential use of the biomarkers CXCL9, CXCL10, CCL20, S100B, and homocysteine to identify disease activity in vitiligo, comparing their values with controls. Methods: A case-control study using previously collected peripheral blood samples from patients aged 18 years or older with a diagnosis of vitiligo and from controls without the disease. The project was approved by the institution's ethics committee. Tests were conducted using ELISA and Luminex kits to measure CXCL9, CXCL10, CCL20, and S100B. For homocysteine, the chemiluminescence method was used.
Study Type
OBSERVATIONAL
Enrollment
85
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande do Sul, Brazil
Biomarkers levels
Assessment of the biomarkers levels in vitiligo group and group control
Time frame: through study completion, an average of 2 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.